BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2019

View Archived Issues

Clotbuster's clot-busting may be beside the point

Read More

Preclinical results of a systemic mRNA therapy for Fabry disease

Read More

Discovery of novel selective hematopoietic prostaglandin D synthase inhibitors

Read More

Takeda's TAK-981 inhibits SUMOylation in vivo, heads to phase I

Read More

Sun Yat-sen University describes mesenchymal stem cells overexpressing CCR2

Read More

AEBi Accelerated Evolution Biotechnologies presents cytotoxic peptides

Read More

New NLRP3 inflammasome inhibitors patented by Inflazome

Read More

Theralase initiates phase II study of TLD-1433 in nonmuscle-invasive bladder cancer

Read More

Prevail Therapeutics describes glucocerebrosidase constructs

Read More

New regenerative therapy developed for Strep pneumonia

Read More

Rapid diagnosis of rare diseases

Read More

KIAA0125 found to be a diagnostic marker in ameloblastoma

Read More

Preclinical characterization of a novel oHSV-expressing bispecific antibody, ONCR-148

Read More

ARHGEF2 as a novel prognosis marker in pancreatic cancer

Read More

Novel animal model of advanced NASH mimics main characteristics of human disease

Read More

FDA approves intravenous Benlysta for pediatric SLE

Read More

FDA approves Praluent to reduce risk of heart attack, stroke and unstable angina

Read More

First-in-human trial scheduled for TGF-beta receptor type-1 inhibitor GFH-018

Read More

Guangdong Zhongsheng Pharmaceutical completes phase I study of ZSP-1273

Read More

Novo Nordisk reports phase III results with Victoza in pediatric type 2 diabetes

Read More

AstraZeneca and Ionis Pharmaceuticals collaborate on antisense oligonucleotide targeting FOXP3

Read More

4D Pharma offers update on development of MRx-0518

Read More

European Commission approves Zynquista for type 1 diabetes

Read More

Conditional marketing authorization granted in E.U. for Ondexxya to reverse factor Xa inhibitors

Read More

Maruishi reports results from Japanese phase III study of Traumakine in ARDS

Read More

ObsEva reports follow-up data from phase III IMPLANT2 study of nolasiban

Read More

Omeicos doses first patient in phase II study of OMT-28 for atrial fibrillation

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

    mRNA flu vaccine can activate broad germinal center response

    BioWorld
    On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing